ライフサイエンスコーパス: subconjunctival

1 Subconjunctival 5-FU injection was performed postoperati

2 ng/ml) injection when compared to posterior subconjunctival (76+/-6 ng/ml) and intravitreal (108+/-3

3 Subconjunctival administration in rat eyes was by inject

4 ocular drug levels for at least 7 days after subconjunctival administration in rats, and prevented co

5 Subconjunctival administration of liposome-encapsulated

6 Subconjunctival administration of neutralizing Ab to IL-

7 Subconjunctival administration of neutralizing antibody

8 Furthermore, subconjunctival administration of optimal range dosages

9 The positive results with subconjunctival administration of P-IQACRG suggest that

10 Subconjunctival administration of rhuPEDF or 34-mer at 0

11 Subconjunctival administration of TPT in FS to one eye a

12 trast, providing additional Slit2 protein by subconjunctival administration resulted in significantly

13 After subconjunctival administration, both budesonide-PLA nano

14 on choroidal neovascularization (CNV) after subconjunctival administration.

15 ion was performed, with recipients receiving subconjunctival alpha-MSH or sham injections twice weekl

16 A combination of subconjunctival and i.p. administration of IL-1beta poly

17 Administration of flagellin via the subconjunctival and intraperitoneal routes 24 h prior to

18 and 2-fold (p = 0.03) higher than posterior subconjunctival and intravitreal injections, respectivel

19 d at 10 and 27.5 minutes, respectively, with subconjunctival and intravitreal injections.

20 eviews currently used techniques of topical, subconjunctival and regional block anesthesia used in op

21 Our results indicated that subconjunctival and subcutaneous injection of HC-HA/PTX3

22 Subconjunctival and submandibular lymph node macrophages

23 Anterior subconjunctival and topical ketorolac were compared to c

24 The successful use of subconjunctival anesthesia demonstrates a new alternativ

25 uenced by the use of intracameral (0.898) or subconjunctival antibiotics (0.331), whereas the use of

26 newer antibiotics and the appropriateness of subconjunctival antibiotics are reviewed.

27 ative antibiotics, intracameral antibiotics, subconjunctival antibiotics, systemic antibiotics, and p

28 r more effective than traditional topical or subconjunctival approaches.

29 To describe the use of subconjunctival bevacizumab (SCB) injection in the combi

30 Eighteen eyes underwent trabeculectomy with subconjunctival bevacizumab injection (2.5 mg/0.1 mL), a

31 Subconjunctival bevacizumab may offer an adjunctive meas

32 Both topical and subconjunctival bevacizumab treatment reduced neovascula

33 Only subconjunctival bevacizumab treatment resulted in signif

34 Adjunctive subconjunctival bevacizumab with trabeculectomy is effec

35 Interestingly, mouse neonates given a subconjunctival BMP4 injection displayed a phenotype res

36 irus-40 T-antigen-positive mice received six subconjunctival CA-4P injections at doses of 0.5, 1.0, 1

37 platin (18.7 mg/kg of body weight), a single subconjunctival carboplatin injection (5.0 mg/400 microL

38 tcome (log rank test, P < 0.001) and reduced subconjunctival collagen deposition (P < 0.01) compared

39 irmed excellent efficacy and tolerability to subconjunctival corticosteroids.

40 rom each group received either of 2 doses of subconjunctival CsA (group A, low-dose CsA; group B, hig

41 High-dose subconjunctival CsA implants do not significantly affect

42 y, either during a cycle of carboplatin (six subconjunctival deliveries) or after the completed cycle

43 Subconjunctival delivery of CA-4P is associated with ext

44 Subconjunctival delivery of neutralizing antibody agains

45 Subconjunctival delivery of paclitaxel effectively inhib

46 onjunctiva, cornea, retina, and sclera after subconjunctival delivery.

47 Bleb characteristics, the presence of subconjunctival drainage, and local reaction to treatmen

48 nt pterygium excision followed by removal of subconjunctival fibrovascular tissue and application of

49 Subconjunctival Fl-PEDF or Fl-ovalbumin administration i

50 Intraoperative complications were subconjunctival hemorrhage (290, 26.2%), anterior capsul

51 ts were recorded, with the exception of mild subconjunctival hemorrhage at the injection site.

52 ted with the surgical procedure and included subconjunctival hemorrhage in 8 patients and ocular hype

53 raocular pressure (IOP), exposure keratitis, subconjunctival hemorrhage, a sore throat, and a transie

54 is, together with conjunctival membranes and subconjunctival hemorrhage, were the earliest signs, pre

55 lion visits were for conjunctivitis (28.0%), subconjunctival hemorrhages (3.0%), and styes (3.8%).

56 This effect was blocked by subconjunctival hexamethonium.

57 MMC-treated tissue demonstrated subconjunctival hypocellularity associated with peripher

58 6 mice after DS, and this was exacerbated by subconjunctival IFN-gamma injection.

59 on, failure of Mucin 5ac (Muc5ac) synthesis, subconjunctival inflammation and epidermal metaplasia in

60 Subconjunctival infusions failed to produce detectable l

61 As an alternative, subconjunctival infusions of drug to the episclera of th

62 The effects of subconjunctival-injected parstatin on corneal neovascula

63 of six New Zealand white rabbits was given a subconjunctival injection at the 12-o'clock position wit

64 Subconjunctival injection for each group (XG-102 90 mug,

65 e VEGFR1_MO, STD MO and PBS groups following subconjunctival injection in mice that underwent normal

66 cinolone acetonide, and PBS groups following subconjunctival injection in mice that underwent penetra

67 40 mug) was administered every 3 months as a subconjunctival injection in only one randomly assigned

68 rance of the nanoparticles in the eyes after subconjunctival injection in vivo.

69 Anterior subconjunctival injection led to high, though short-live

70 Subconjunctival injection may be a useful approach for d

71 -inflammatory drug (NSAID) or intraoperative subconjunctival injection of 2 mg triamcinolone acetonid

72 The time course and extent of mydriasis from subconjunctival injection of 2% pirenzepine were determi

73 Patients were administered a single subconjunctival injection of 250 muL XG-102 90 mug (n =

74 The study drug was administered as a single subconjunctival injection of 30 muL (1320 mug) sirolimus

75 eedling with HA-5FU mixture or needling with subconjunctival injection of 5FU solution alone.

76 The right eye of 15 mice received a single subconjunctival injection of a 1.5-microL solution of 0.

77 ed keratitis was significantly reduced after subconjunctival injection of a monoclonal antibody (mAb)

78 nase modulation after AA treatment, a single subconjunctival injection of AA (300 microg) was deliver

79 Conversely, subconjunctival injection of Ab to ICAM-1 did not impair

80 Subconjunctival injection of Ab to PECAM-1 significantly

81 ek-old, LH(BETA)T(AG) mice received a single subconjunctival injection of anecortave acetate (1200, 6

82 ek-old, LH(BETA)T(AG) mice received a single subconjunctival injection of anecortave acetate (600, 30

83 The fellow eye was given a subconjunctival injection of balanced salt solution.

84 Postoperative subconjunctival injection of bevacizumab is associated w

85 Depletion of local macrophages, through subconjunctival injection of clodronate liposome, attenu

86 We induced mast cell degranulation by local subconjunctival injection of compound 48/80.

87 Subconjunctival injection of disodium cromoglycate signi

88 16-week-old mice were treated with a single subconjunctival injection of either anecortave acetate (

89 Subconjunctival injection of HA-5FU to revive bleb funct

90 help prove the concept that subcutaneous and subconjunctival injection of HC-HA/PTX3 is a novel appro

91 Anterior subconjunctival injection of ketorolac produced high int

92 s showed that different suturing techniques, subconjunctival injection of long-acting steroid, and ta

93 CpG DNA, which binds TLR9, was tested after subconjunctival injection of mice with control or CpG DN

94 Subconjunctival injection of mitomycin C in the rabbit p

95 Subconjunctival injection of MMP13i prior to P. aerugino

96 Strikingly, subconjunctival injection of P-IQACRG was very effective

97 In the mouse cornea, subconjunctival injection of the morpholino-inhibited co

98 Dutch-belted rabbits received a subconjunctival injection of triamcinolone acetonide to

99 A single subconjunctival injection of XG-102 at the end of ocular

100 venous delivery than after focal delivery by subconjunctival injection or CCI.

101 oroid, vitreous humor, and optic nerve after subconjunctival injection or iontophoretic carboplatin d

102 ix cycles of 5.0 mg carboplatin delivered by subconjunctival injection or six transscleral carboplati

103 to prevent corneal graft rejection following subconjunctival injection provided initially during tran

104 red to the mouse retina and uveal tissues by subconjunctival injection through transscleral diffusion

105 either mBD1 or mBD2 small interfering RNA by subconjunctival injection together with topical applicat

106 ic preoperative antibiotics or postoperative subconjunctival injection was associated with a 40% to 5

107 lated-P-IQACRG delivered via intravitreal or subconjunctival injection was demonstrated by avidin-bio

108 on of neutrophil recruitment was achieved by subconjunctival injection with an antibody against macro

109 Infected BALB/c mice also were tested after subconjunctival injection with recombinant murine (rm)ST

110 with HSV-1 were vaccinated periocularly (by subconjunctival injection) with gD1 and adjuvant, gD2 an

111 Ketorolac was administered by anterior subconjunctival injection, posterior periocular injectio

112 It was reported that, after subconjunctival injection, RNA nanoparticles with tri-wa

113 er: suprachoroidal > intravitreal >posterior subconjunctival injection.

114 Cs were selectively depleted by timed local (subconjunctival) injection of diphtheria toxin (DT) into

115 Daily subconjunctival injections (0.01-10 pmol/d protein) were

116 = 5) 10 weeks of age received two 20-microL subconjunctival injections delivered with a 72-hour inte

117 Subconjunctival injections of 0.0002% to 0.2% pirenzepin

118 Subconjunctival injections of 0.002% or less pirenzepine

119 Subconjunctival injections of 0.02% or greater pirenzepi

120 d to receive a postoperative course of seven subconjunctival injections of bevacizumab (1.25 mg, 25 m

121 d to receive a postoperative course of seven subconjunctival injections of CAT-152 (1 mg/mL), 5-FU (5

122 ce was tested by depleting macrophages using subconjunctival injections of clodronate-containing lipo

123 Control mice received two subconjunctival injections of DMSO or of saline solution

124 concentration of 0.2 mg/mL or postoperative subconjunctival injections of either ilomastat or phosph

125 randomly allocated to receive postoperative subconjunctival injections of either phosphate-buffered

126 group of mice of both strains also received subconjunctival injections of exogenous IFN-gamma or veh

127 BETA)T(AG) mice were treated with six serial subconjunctival injections of focally delivered carbopla

128 g, 16-week-old mice were treated with single subconjunctival injections of the selective vascular-tar

129 ocal recombinant Gal-1 (rGal-1) treatment by subconjunctival injections significantly diminishes P. a

130 arboplatin was administered through biweekly subconjunctival injections to right eyes only for 3 week

131 when compared to intravitreal and posterior subconjunctival injections.

132 Subconjunctival inoculation of spantide I during the cli

133 Subconjunctival inoculation of spantide I, SP receptor a

134 n of endogenous MIP-2 and KC was achieved by subconjunctival inoculation of the appropriate antibody.

135 conjunctiva, epidermis, hair follicles, and subconjunctival lymphoid follicles.

136 ft eye with a slight elevation, suggesting a subconjunctival mass.

137 Subconjunctival mitomycin C injection may cause limbal s

138 country, the American patients have not had subconjunctival nodules but have manifested more invasiv

139 its, catheters were placed anteriorly in the subconjunctival or intrascleral space and infused with G

140 o-penta-acetic acid (Gd-DTPA) infused in the subconjunctival or intrascleral space was investigated b

141 Focal administration of carboplatin using subconjunctival or noninvasive CCI safely and effectivel

142 ere noted; procedure-related adverse events (subconjunctival or subretinal haemorrhage and mild cell

143 Dawley rats after suprachoroidal, posterior subconjunctival, or intravitreal injections.

144 Subconjunctival parstatin inhibited corneal neovasculari

145 S in one eye was injected into the posterior subconjunctival (periocular) space in rats under anesthe

146 ddition, these data prompt the proposal that subconjunctival protein delivery may represent a feasibl

147 art review of 4 patients diagnosed with late subconjunctival relapse of previously resected iris mela

148 dian of 2.5 years (mean: 7.7 years) from the subconjunctival relapse, no further episodes of intraocu

149 ls were treated with intravenous (IV) and/or subconjunctival (SC) Cl(2)MDP-LIP or PBS-LIP at the foll

150 Macrophage depletion was performed by subconjunctival (SC) delivery of liposomal clodronate.

151 terior subtenon (PST), retrobulbar (RB), and subconjunctival (SC) injection.

152 benefit as a postoperative agent to prevent subconjunctival scarring after glaucoma filtration surge

153 ificantly improved surgical outcome, reduced subconjunctival scarring, and minimized the risk of corn

154 ter virus infection was achieved by repeated subconjunctival (SCJ) and/or intravenous (IV) injection

155 Subconjunctival sirolimus appears to be well tolerated i

156 Subconjunctival sirolimus leads to a short-term reductio

157 Subconjunctival sirolimus may not be beneficial in the p

158 Repeated subconjunctival sirolimus was well-tolerated in patients

159 limination rate constant of Gd-DTPA from the subconjunctival space into the episcleral veins and conj

160 Cultured RPE cells implanted in the subconjunctival space of syngeneic mice elicited an inte

161 Gd-DTPA were manufactured and placed in the subconjunctival space on the episclera or in the vitreou

162 n, continuous release of cyclosporine in the subconjunctival space with the episcleral implant was an

163 ass through the trabeculectomy site into the subconjunctival space, and an extra amount was injected

164 anterior chamber, the subretinal space, the subconjunctival space, and underneath the kidney capsule

165 f newborn C57BL/6 mice were implanted in the subconjunctival space, the anterior chamber, or the subr

166 d to control as well as topical and anterior subconjunctival steroid treatments in uveitis induced by

167 let cell expansion that invaginates into the subconjunctival stroma in the mouse eye.

168 nd promoted the formation of a nearly normal subconjunctival stroma.

169 ells than normal specimens were noted in CCh subconjunctival tissue and Tenon's capsule.

170 Depletion of macrophages in the subconjunctival tissue before corneal infection was not

171 arying levels of TGF-beta in the aqueous and subconjunctival tissues may thus significantly modify th

172 terally with a single 30-microL injection of subconjunctival TPT in FS (0.025, 0.05, 0.1, 0.2, 0.4, 0

173 lar area was 55% (P < 0.05) by week 8 in the subconjunctival treatment group and 33% (P = 0.15) in th

174 However, in the subconjunctival treatment group, 33% of corneal grafts s

175 with systemic dexamethasone or intravitreal/subconjunctival triamcinolone.

176 isk host beds, and graft recipients received subconjunctival vascular endothelial growth factor (VEGF

177 Postoperative subconjunctival wound healing remains the commonest caus